Statins and risk reduction in hepatocellular carcinoma: Fact or fiction?

Journal of Clinical Oncology

Volumn 30, Issue 20, 2012, Pages 2569-2570

  Singh, Preet Paul ^a   Singh, Siddharth ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIVIRUS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA;

ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; DIABETES MELLITUS; DRUG POTENTIATION; HUMAN; LETTER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RISK REDUCTION;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS; MALE;

EID: 84864041123     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.2179     Document Type: Letter

References (10)

1. Tsan YT, Lee CH, Wang JD, et al: Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 30:623-630, 2012
2. Wang P, Kang D, Cao W, et al: Diabetes mellitus and risk of hepatocellular carcinoma: A systematic review and meta-analysis. Diabetes Metab Res Rev 28:109-122, 2012
3. Yang WS, Va P, Bray F, et al: The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: A meta-analysis of prospective cohort studies. PloS One 6:e27326, 2011
4. Wang C, Wang X, Gong G, et al: Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta-analysis of cohort studies. Int J Cancer 130:1639-1648, 2012
5. Lai SW, Chen PC, Liao KF, et al: Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: A population-based cohort study. Am J Gastroenterol 107:46-52, 2012
6. Hassan MM, Curley SA, Li D, et al: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116:1938-1946, 2010
7. Donadon V, Balbi M, Mas MD, et al: Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30:750-758, 2010
8. Zhou G, Myers R, Li Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001 (Pubitemid 32995375)
9. Ben Sahra I, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576-3586, 2008 (Pubitemid 351793803)
10. Okumura T: Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol 45:1097-1102, 2010